interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Celecoxib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Celecoxib, and who makes it?

Celecoxib appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 18 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 15.4 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Celecoxib3 dosage-form groups in the Orange Book
18generic makers listed
  1. Celecoxib appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 18 generic makers listed as marketed across them.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 15.4 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Four or more generic makers listed

Brand listed as marketed: Celebrex. 18 generic makers with 67 generic products listed as marketed; the first generic approval is dated 30 May 2014.

19952000200520102015202020252030018brand 1998Teva Pharmaceuticals Usa Inc, first approval 30 May 2014Lupin Ltd, first approval 29 October 2014Watson Laboratories Inc, first approval 11 February 2015Apotex Inc, first approval 2 June 2015Alembic Pharmaceuticals Ltd, first approval 21 August 2015Cipla Ltd, first approval 23 September 2015Torrent Pharmaceuticals Ltd, first approval 23 December 2015Aurobindo Pharma Ltd, first approval 1 February 2016Macleods Pharmaceuticals Ltd, first approval 16 March 2016Cspc Ouyi Pharmaceutical Co Ltd, first approval 23 January 2018Micro Labs Ltd, first approval 30 April 2018Qingdao Baheal Pharmaceutical Co Ltd, first approval 7 August 2019Cadila Pharmaceuticals Ltd, first approval 14 November 2019Pharmazone, first approval 27 November 2019Tianjin Tianyao Pharmaceuticals Co Ltd, first approval 25 February 2020Pharmobedient Consulting Llc, first approval 6 March 2020Nanjing Simcere Dongyuan Pharmaceutical Co Ltd, first approval 13 May 2020Sciegen Pharmaceuticals Inc, first approval 3 December 2020data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Teva Pharmaceuticals Usa Inc30 May 20144
Lupin Ltd29 October 20144
Watson Laboratories Inc11 February 20154
Apotex Inc2 June 20153
Alembic Pharmaceuticals Ltd21 August 20154
Cipla Ltd23 September 20154
Torrent Pharmaceuticals Ltd23 December 20154
Aurobindo Pharma Ltd1 February 20164
Macleods Pharmaceuticals Ltd16 March 20164
Cspc Ouyi Pharmaceutical Co Ltd23 January 20183
Micro Labs Ltd30 April 20184
Qingdao Baheal Pharmaceutical Co Ltd7 August 20194

6 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Elyxyb. No generic is listed as marketed.

2020202520302035204001brand 2020data datePatent 10722456 listed to expire 27 May 2036Patent 10799517 listed to expire 27 May 2036Patent 9949990 listed to expire 27 May 2036Patent 9795620 listed to expire 27 May 2036Patent 9572819 listed to expire 27 May 2036Patent 10376527 listed to expire 27 May 2036
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 27 May 2036Patent 10722456 drug product
  • 27 May 2036Patent 10799517 drug product
  • 27 May 2036Patent 9949990 drug product
  • 27 May 2036Patent 9795620 drug product
  • 27 May 2036Patent 9572819 drug product
  • 27 May 2036Patent 10376527 drug product

Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Vyscoxa. No generic is listed as marketed.

20202025203020352040204501brand 2025data datePatent 12678405 listed to expire 17 September 2045
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 17 September 2045Patent 12678405 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.